L3VLUP
ProSign in

TMO · LLY in the 13F filings

Two to four stocks side by side among the 95 tracked managers: who lists them, how that has moved, who bought and sold in a quarter, and which managers hold more than one.

TMOLLY
Quarter
Q2 2026Q1 2026Q4 2025Q3 2025Q2 2025Q1 2025Q4 2024Q3 2024Q2 2024Q1 2024Q4 2023

Holders over time

Tracked managers listing each stock every quarter, at least, or their combined reported value. A gap is a quarter in which no tracked manager listed it. Click a quarter to compare there.
  • TMO
  • LLY
0204060202120222023202420252026
Holders and value by quarter
QuarterTMOLLY
Q3 202029 holders, $38.9bn33 holders, $14.1bn
Q4 202033 holders, $39.2bn29 holders, $17.3bn
Q1 202135 holders, $36.5bn24 holders, $23.0bn
Q2 202133 holders, $38.3bn24 holders, $27.8bn
Q3 202132 holders, $42.6bn31 holders, $29.9bn
Q4 202138 holders, $50.1bn31 holders, $34.7bn
Q1 202232 holders, $43.2bn24 holders, $35.3bn
Q2 202233 holders, $38.9bn33 holders, $42.7bn
Q3 202226 holders, $34.3bn31 holders, $43.4bn
Q4 202229 holders, $37.0bn31 holders, $46.6bn
Q1 202335 holders, $37.1bn33 holders, $44.3bn
Q2 202339 holders, $33.5bn37 holders, $59.6bn
Q3 202339 holders, $32.6bn44 holders, $67.6bn
Q4 202341 holders, $32.7bn45 holders, $73.6bn
Q1 202430 holders, $34.1bn41 holders, $95.3bn
Q2 202438 holders, $30.6bn43 holders, $110bn
Q3 202430 holders, $33.8bn45 holders, $107bn
Q4 202436 holders, $27.6bn46 holders, $93.9bn
Q1 202531 holders, $24.2bn42 holders, $98.4bn
Q2 202539 holders, $18.8bn43 holders, $93.2bn
Q3 202532 holders, $21.9bn39 holders, $86.7bn
Q4 202532 holders, $29.9bn41 holders, $123bn
Q1 202634 holders, $24.4bn39 holders, $106bn
Q2 202636 holders, $26.4bn44 holders, $132bn
TMO

Thermo Fisher Scientific Inc

Holders
32
Reported value
$29.9bn
Buyers
27
Sellers
20

Breadth +7 among 92 comparable managers.

IndustrialsHealthcare: biopharma and medtech · L3VLUPIndustrials and automation · L3VLUP
LLY

Eli Lilly & Co

Holders
41
Reported value
$123bn
Buyers
25
Sellers
22

Breadth +3 among 92 comparable managers.

Pharmaceuticals and biotechnologyHealthcare: biopharma and medtech · L3VLUPPharmaceutical preparations

Who holds both, Q4 2025

Among the 49 tracked managers listing any of them. "Only" is about listed positions: a manager may hold the other below its listed range.

Only TMO (8)

Baillie Gifford & Co, Farallon Capital Management LLC, Glenview Capital Management LLC, Markel Group Inc, MFS Investment Management, Third Point LLC, Verition Fund Management LLC, Viking Global Investors LP

Only LLY (17)

Acadian Asset Management LLC, AQR Capital Management LLC, Balyasny Asset Management LLC, Bridgewater Associates LP, D. E. Shaw & Co., Freestone Grove Partners LP, Hudson Bay Capital Management LP, Man Group PLC, Millennium Management LLC, Moore Capital Management LP, Quantbot Technologies LP, Renaissance Technologies LLC, Soros Fund Management LLC, Squarepoint Ops LLC, Tudor Investment Corp, Walleye Capital LLC, Winton Group Ltd

How much of the picture this is

A 13F is a manager’s long US-listed equity book at a quarter end, filed up to 45 days later. Buyers and sellers count comparable managers (those that filed both quarters) by shares, so a rise in value with no rise in shares is the price. Large books are listed to their largest positions. These are 95 tracked managers, not the institutional market.

Back to the 13F Explorer →